Multiple observations of negative associations between statin use and PSA levels, when combined with suggestions of possible biological mechanisms, have led to a hypothesis that lower PSA levels can be an indication that statins may reduce the risk of developing prostate cancer or the risk of disease progression [8]. Here, KLK3 is linked to prostate carcinoma.